Cellular responses to modified Plasmodium falciparum MSP119 antigens in individuals previously exposed to natural malaria infection by Okafor, Christian MF et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Malaria Journal
Open Access Research
Cellular responses to modified Plasmodium falciparum MSP119 
antigens in individuals previously exposed to natural malaria 
infection
Christian MF Okafor*1,5, Chiaka I Anumudu1, Yusuf O Omosun1,6, 
Chairat Uthaipibull3,7, Idowu Ayede2, Henrietta O Awobode1, 
Alex B Odaibo1, Jean Langhorne3, Anthony A Holder3, Roseangela I Nwuba1 
and Marita Troye-Blomberg4
Address: 1Cellular Parasitology Programme, Department of Zoology University of Ibadan, Ibadan, Nigeria, 2Oni Memorial Children's Hospital, 
Ring Road, Ibadan, Nigeria, 3Division of Parasitology, MRC National Institute for Medical Research, Mill Hill, London NW7 1AA, UK, 
4Department of Immunology, Wenner-Gren Institute, Arrhenius Laboratories, Stockholm University, Stockholm, Sweden, 5College of Art and 
Sciences, Northwest University, 5520, 108th Ave. NE, Kirkland WA 98033, USA, 6Department of Biotechnology, Bells University of Technology, 
Sango-Otta, Nigeria and 7Protein-Ligand Engineering and Molecular Biology Laboratory, National Center for Genetic Engineering and 
Biotechnology (BIOTEC), Thailand Science Park, Pathumthani, Thailand
Email: Christian MF Okafor* - cmfokafor2001@yahoo.com; Chiaka I Anumudu - cianumudu@yahoo.com; 
Yusuf O Omosun - yusufomosun@yahoo.com; Chairat Uthaipibull - chairat@biotec.or.th; Idowu Ayede - idayede@yahoo.co.uk; 
Henrietta O Awobode - awobodet@yahoo.com; Alex B Odaibo - abodaibo@yahoo.com; Jean Langhorne - jlangho@nimr.mrc.ac.uk; 
Anthony A Holder - aholder@nimr.mrc.ac.uk; Roseangela I Nwuba - rnwuba@yahoo.com; Marita Troye-Blomberg - marita@imun.su.se
* Corresponding author    
Abstract
Background: MSP1 processing-inhibitory antibodies bind to epitopes on the 19 kDa C-terminal
region of the Plasmodium falciparum merozoite surface protein 1 (MSP119), inhibiting erythrocyte
invasion. Blocking antibodies also bind to this antigen but prevent inhibitory antibodies binding,
allowing invasion to proceed. Recombinant MSP119  had been modified previously to allow
inhibitory but not blocking antibodies to continue to bind. Immunization with these modified
proteins, therefore, has the potential to induce more effective protective antibodies. However, it
was unclear whether the modification of MSP119 would affect critical T-cell responses to epitopes
in this antigen.
Methods: The cellular responses to wild-type MSP119 and a panel of modified MSP119 antigens
were measured using an in-vitro assay for two groups of individuals: the first were malaria-naïve and
the second had been naturally exposed to Plasmodium falciparum infection. The cellular responses
to the modified proteins were examined using cells from malaria-exposed infants and adults.
Results: Interestingly, stimulation indices (SI) for responses induced by some of the modified
proteins were at least two-fold higher than those elicited by the wild-type MSP119. A protein with
four amino acid substitutions (Glu27→Tyr, Leu31→Arg, Tyr34→Ser and Glu43→Leu) had the
highest stimulation index (SI up to 360) and induced large responses in 64% of the samples that had
significant cellular responses to the modified proteins.
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Conclusion: This study suggests that specific MSP119 variants that have been engineered to
improve their antigenicity for inhibitory antibodies, retain T-cell epitopes and the ability to induce
cellular responses. These proteins are candidates for the development of MSP1-based malaria
vaccines.
Background
The development of an effective malaria vaccine remains
a major public health challenge. Merozoite surface pro-
tein (MSP)-1 of Plasmodium falciparum is being developed
as a vaccine candidate to protect against the erythrocytic
stages of the malaria parasite [1,2]. Much of the work has
been focused on the 19 kDa C-terminal region of MSP1
(called MSP119[3]). Protection against challenge infection
following immunization in rodent and monkey models
of malaria has been reported [4-11]. However, sero-epide-
miological studies [12-16] and vaccine trials [17] in
human populations have given conflicting results con-
cerning the protective role of anti-MSP1 antibodies, which
may be explained by differences in the fine specificities of
the MSP119-specific antibodies [18,19]. It can be con-
cluded from these studies that in the humoral control of
malaria infection, the fine specificity of the antibody
response may be crucial to inhibit erythrocyte invasion by
merozoites.
The MSP1 precursor is cleaved into four fragments on the
merozoite surface and at invasion the C-terminal 42 kDa
fragment (MSP142) is processed further into two smaller
fragments: a 33 kDa polypeptide (MSP133) and the C-ter-
minal MSP119, which remains on the parasite surface dur-
ing invasion of red blood cells (RBC). MSP1 has been
reported to elicit three types of antibody that can bind
MSP142[2,20,21]. These are a) inhibitory antibodies,
which inhibit the cleavage of MSP142 and thus invasion of
RBC; b) blocking antibodies, which have overlapping spe-
cificities and compete with inhibitory antibodies for bind-
ing to the antigen, thereby allowing processing and
invasion to occur even in the presence of inhibitory anti-
bodies; and c) neutral antibodies that are neither inhibi-
tory nor blocking. Significantly, it has been shown that all
these types of MSP119-specific antibodies are part of the
natural immune response to MSP1 in malaria-exposed
individuals [22,23]. Thus, the rational design of an MSP1-
based malaria vaccine for the preferential induction of
processing-inhibitory antibodies with the appropriate
specificities is an important goal. The relative abundance
of these protective antibodies in relation to the detrimen-
tal (blocking) antibodies in any infection is one of the
important factors that may determine the outcome of that
infection [2,3,20,22].
The MSP119 epitopes recognized by inhibitory and block-
ing monoclonal antibodies (mAbs) have been mapped
using site-directed mutagenesis, PEPSCAN, and nuclear
magnetic resonance (NMR) [21,24,25]. A number of sin-
gle and multiple amino acid substitutions in MSP119 has
been made, which had either no effect, or reduced, or
completely abolished the binding of individual mAbs
[21]. Recent data have shown that polyclonal antibodies
in sera obtained from individuals living in a malaria
endemic area recognize and bind to the modified antigens
[22,23]. A vaccine based on one of these modified pro-
teins could be designed to induce inhibitory but not
blocking Abs and thus provide a focused polyclonal anti-
body response to inhibit RBC invasion and cleavage of
MSP1 [21,22].
CD4+ T-cell responses, providing help for MSP1-specific
B-cell responses, are essential for protective immunity in
rodent models of malaria, in protective immunity
induced by immunization with MSP119[26]. Since it is
possible that the amino acid substitutions may alter the
pattern and kinetics of MSP119  antigen processing of
within the MHC class II pathway, and thus the peptides
presented, it will be important to determine whether the
variant MSP1 molecules are recognized by immune cells
obtained from individuals naturally primed by malaria
infection. Some reports have suggested that T-cell
responses to MSP1 in malaria-exposed donors are poor
[27,28], possibly because of the difficulty in processing
the highly disulfide bonded globular MSP119 [27,29,30].
Also, the common occurrence of high background
responses in both unexposed and exposed donors makes
it difficult to demonstrate T-cell responses in field sam-
ples. The study described here was carried out to deter-
mine whether modified MSP119 antigens were recognized
by immune cells from naturally exposed and immune
individuals living in a malaria endemic area, and whether
modification of the critical T cell epitopes of MSP119
would enhance or compromise cellular responses. Results
from this study show that variant MSP119 with two or
more amino acid substitutions not only stimulated PBMC
from exposed individuals but also induced proliferative
responses in vitro of greater magnitude than the wild-type
(WT) antigen. These results suggest that these modified
MSP1 proteins may be suitable candidates for a malariaMalaria Journal 2009, 8:263 http://www.malariajournal.com/content/8/1/263
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vaccine that would induce both protective antibodies and
suitable cellular responses.
Methods
Subjects and samples
Volunteers were recruited in Ibadan, Nigeria where P. fal-
ciparum malaria is perennial. High malaria transmission
occurs from April to November, corresponding to the
rainy season (March to October), all samples were col-
lected in March. The study protocol was reviewed and
approved by the Joint University of Ibadan/University
College Hospital Ethical committee. Informed consent
was obtained from all participating individuals or legal
guardians of children enrolled in the study. The donors
were divided into two groups; the first was between three
months and seven years of age (six individuals) and had
clinical malaria symptoms, while the second aged
between 13 yrs and 43 yrs (30 individuals) was without
clinical malaria at recruitment. Venous blood (up to 4 ml
from children and 7 ml from adults) was collected in
heparinized tubes and transported immediately in insu-
lated boxes to the laboratory for processing at the Depart-
ment of Immunology, Wenner-Gren Institute, Stockholm
University, Sweden. Giemsa-stained thick-blood films
were examined for the presence of malaria parasites. A
group of seven malaria-unexposed European donors pro-
vided control samples for the study.
Peripheral blood mononuclear cells (PBMC)
Human PBMC were harvested from whole blood approx-
imately 24 hrs after phlebotomy. PBMC were prepared by
Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) density
gradient centrifugation according to the manufacturers'
instructions. The harvested cells were suspended in freez-
ing medium [10% dimethyl sulfoxide (DMSO), 20% fetal
calf serum (FCS), RPMI 1640, HEPES and L-glutamine],
frozen at 1°C min-1 to -70°C in plastic containers (Nal-
gene Cryo, Nalge Company, USA), and then transferred
into liquid nitrogen until used in in vitro assays. The cells
had a demonstrated >95% viability when compared with
frozen cells collected in Sweden.
Antigens
Cells in the proliferation assays were stimulated by anti-
gens at a predetermined final concentration of 1 μg/ml.
Wild-type (WT) and modified MSP1 proteins
The recombinant wild-type and modified MSP119 anti-
gens fused to Schistosoma japonicum glutathione S-trans-
ferase (GST) have been described previously [21]. Table 1
shows the specific modifications in the primary sequence
of the MSP119 antigens used; residues are numbered from
the N-terminus of MSP119.
P. falciparum antigen
Crude P. falciparum antigen (F32) was used as a positive
control for confirming previous infection or lack of expo-
sure to P. falciparum in exposed and naïve individuals
[31].
Control antigens
Phytohemagglutinin (PHA; Sigma, Poole, UK) was used
as positive control for testing lymphocyte viability and
responsiveness. Recombinant GST was used as a control
antigen.
Cell proliferation assays
Frozen PBMCs were thawed, washed three times, and
resuspended at a final concentration of 106 viable cells/ml
in complete medium [RPMI 1640 containing 2 mM L-
glutamine, 50 U/ml penicillin, 0.1 mg/ml streptomycin,
10 mM HEPES, 0.22% (vol/vol) sodium bicarbonate and
10% heat-inactivated non-immune FCS]. The cells were
then plated into sterile, round-bottomed 96-well micro-
titer plates at 105  viable cells/well in 100 μl culture
medium. Antigens were diluted to 2 μg/ml in complete
medium and 100 μl of the antigen solution added to the
wells containing the cells (in triplicates), giving a final
Table 1: The panel of modified MSP119 antigens
Amino acid substitutions in the primary sequence
Position(s) Wildtype residue Variant residue
Single amino acid
6 Gln Ile
14 Gln Arg
32 Leu Arg
33 Asn Ile
40 Lys Ile
Multiple amino acids
12+28 Cys+Cys Ile+Trp
34+39 Tyr+Asp Ser+Thr
43+48 Glu+Thr Leu+Lys
15+27+31+43 Asn+Glu+Leu+Glu Arg+Tyr+Arg+Leu
27+31+34+43 Glu+Leu+Tyr+Glu Tyr+Arg+Ser+Leu
Position in the sequence is numbered from the N-terminus of MSP119Malaria Journal 2009, 8:263 http://www.malariajournal.com/content/8/1/263
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antigen concentration of 1 μg/ml. Unstimulated cultures
served as negative controls, and those stimulated with
PHA as positive controls. The plates were incubated at
37°C in a humidified atmosphere containing 5% CO2 for
6 days. On the 5th day of incubation, 100 μl of superna-
tant were removed from each well and replaced with 100
μl of fresh medium containing [3H] thymidine (1 μCi/
well; Amersham Life Sciences, Little Chalfont, UK) for a
further 16-18 hours. Cells were harvested onto filter mats
using a cell harvester (Tomtec) and incorporation of radi-
oactivity was measured using a Microbeta counter. Prolif-
erative responses expressed as the geometric mean of
radioactivity incorporation in counts per minute were
determined for each antigen, and the stimulation index
(SI) was calculated as the ratio of incorporation by anti-
gen-stimulated cells to that of the unstimulated control
cells. Subjects whose cells responded to one or more vari-
ants with a SI two-fold or more above that of the GST con-
trol were grouped as responders whereas others with a SI
similar to or lower than that of GST were not considered
to be responders. This cut-off was set to ensure that we
were measuring a response to MSP119 and not GST.
Statistics
Correlation coefficients and stimulation indices were
plotted using SPSS and MS Excel software (p = 0.05 was
considered significant).
Results
Parasitemia of donors
Microscopic examination of blood smears from the 36
donors in this study showed that 20 (56%) were positive
for P. falciparum, while no parasites were detected in the
blood of the remaining donors. Parasite burden in indi-
Mean T cell responses in malaria-exposed and un-exposed individuals Figure 1
Mean T cell responses in malaria-exposed and un-exposed individuals. Responses to the wildtype-MSP119, modified 
MSP119 antigens, PHA, GST and F32 (a crude malarial antigen preparation) in seven malaria-exposed individuals (shaded boxes) 
and five unexposed malaria-naïve individuals (open boxes), as measured by stimulation index (SI). The malaria-exposed individ-
uals showed significantly higher responses to all the malaria antigens than the malaria-unexposed individuals (P = 0.001).Malaria Journal 2009, 8:263 http://www.malariajournal.com/content/8/1/263
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viduals decreased significantly with increasing age among
the subjects (p = 0.021). Among the parasitemic subjects,
6 of 20 were symptomatic at the time of recruitment with
parasite densities ranging between 280 and 72,727 para-
sites/μl blood, while the remaining 14 donors who were
asymptomatic had a parasitemia that ranged between 40
and 600 parasites/μl blood (data not shown).
Cellular proliferation in response to the wild-type and 
modified MSP119 antigens
The stimulatory capacity of each antigen in the panel was
assessed. In vitro cellular responses to the WT MSP119 and
a panel of ten variants with one or more amino acid sub-
stitution [21] (Table 1) were studied, using PBMC from
the 36 naturally exposed and 7 malaria-naïve donors. Pro-
liferative responses to both the WT and the modified anti-
gens were observed and a stimulation index was
calculated for each. Though not all the malaria-exposed
donors responded to both WT and modified antigens,
these individuals had significantly higher proliferative
responses than the malaria naïve group (Figure 1). In
addition, for the malaria-exposed individuals, it was
observed that most of the responses to the modified
MSP119  antigens were significantly greater than the
response to the WT molecule.
Cells from 14 (39%) of the exposed individuals had a sig-
nificant proliferative response to the panel of MSP119 anti-
gens (SI range >2 - 360). These individual were grouped as
responders, while the remaining 61% of malaria-exposed
donors that responded poorly to the antigens were
grouped as non-responders. A modified protein,
27+31+34+43 with four amino acid substitutions (Table
1), had the most intense and consistently highest T-cell
stimulatory effect, with a mean SI as high as 360 and elic-
ited a response in the greatest number of donors: nine of
Prevalence of response to MSP119 variant and wildtype antigens Figure 2
Prevalence of response to MSP119 variant and wildtype antigens. Prevalence of T cell responses to the antigens for 14 
individuals that were identified as high responders. The observed responses to the variants (shaded bars) were significantly 
higher than the response to the WT-MSP119 (open bar). The responses to the variants 43+48 and 33 were higher than that to 
the GST-control but lower than that to WT-MSP119.Malaria Journal 2009, 8:263 http://www.malariajournal.com/content/8/1/263
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14 (64%) responders had a significant response to this
variant (Figure 2). In these same nine individuals, the
responses to the 27+31+34+43 variant were significantly
higher than the responses to the wild-type (WT-MSP119)
antigen. Using cells collected from the same individual
the SI was 240-fold greater than the SI seen in response to
WT-MSP1. More than half of the nine (5/9) individuals
that responded to the 27+31+34+43 variant had a SI that
was at least five-fold higher than that seen in response to
the wild-type antigen.
Three single amino acid substitution variants 6, 14 and 40
(Table 1) and the 15+27+31+43 variant (a four-residue
substitution variant) all elicited high responses in 5/14
(36%) of the responders (Figure 2). Four of 14 (27%)
responders had a significant response to the 12+28 variant
which lacks a disulfide bond (Cys12→Ile and
Cys28→Trp). The 34+39 variant (Tyr34→Ser,
Asp39→Thr) elicited a response in only one of the
responders. Two of the 14 (14%) responders had
responses to the 33 (Asn33→Ile) and 43+48 (Glu43→Leu
and Thr48→Lys) variants; the intensity of these responses
were higher than the responses to the GST control protein
but lower than the responses to WT-MSP119.
Intense responses were also elicited by the 15+27+31+43
variant in five of the responders with a mean SI of 314.6.
Three out of six individuals that responded to
15+27+31+43 had a SI that was at least five-fold greater
than that to the wild-type protein. Variants 14 and 12+28
induced a mean SI of 315.7 and 269, respectively. The
data revealed that all the high stimulation indices (SI
>100), occurred with the MSP119 variants containing two
or more amino acid substitutions except for the variant 14
which had a single amino acid change of Gln to Arg at
position 14. All the variants in the panel that induced an
intense response consistently induced a ≥3-fold stronger
response than the WT protein.
The difference between the two 4-amino acid substitution
variants, 27+31+34+43 and 15+27+31+43 is a substitu-
tion Asn15→Arg in 15+27+31+43 and Tyr34→Ser in
Cellular responses to wildtype-MSP119 antigen and the two variants with four amino acid substitutions Figure 3
Cellular responses to wildtype-MSP119 antigen and the two variants with four amino acid substitutions. 
27+31+34+43 and 15+27+31+43 MSP119 variants in 5 individuals of different ages and malaria exposure. OM21 and OM08 had 
clinical presentation but the others did not. The stimulation indices (SI) for the 27+31+34+43 (dotted boxes) and 
15+27+31+43 (shaded box) variants were significantly higher than the SI for the WT-MSP119 antigen (clear boxes).Malaria Journal 2009, 8:263 http://www.malariajournal.com/content/8/1/263
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27+31+34+43. The responses to these two variants were
compared in five individuals that responded to both vari-
ants (Figure 3). For this small group, the data suggested
that the 27+31+34+43 variant preferentially induced a
response in cells obtained from children whereas
15+27+31+43 had a greater effect with cells from adults.
The response to the WT antigen did not change signifi-
cantly with increasing age (Figure 3).
Discussion
This study investigated the proliferative cellular responses
to wild-type MSP119 and several variant proteins in indi-
viduals naturally exposed to the P. falciparum parasite. The
results revealed that the modified MSP119  antigens
induced stronger and more frequent responses as com-
pared to the wild type MSP1. In particular, the responses
seen to most of the modified antigens with two or more
amino acid substitutions were stronger than the response
to the native antigen. These findings indicate that the anti-
genic epitopes in some of the MSP119 variants were not
compromised by the specific amino acid modifications;
some of these modifications actually enhanced the
response to the proteins.
The MSP-119 sequence is highly conserved, largely with
diversity at only four positions in its 96 amino acid resi-
dues [32]. This study has shown that selective replacement
of up to four amino acid residues in the MSP119 sequence
did not compromise the linear epitopes that are recog-
nized by T-cells.
In the population tested, a response to one or more vari-
ants was noted in 38% of individuals, whereas only 22%
had a proliferative response to WT-MSP119. In previous
work to evaluate human T-cell responses to WT-MSP119
antigen a prevalence of 26% responders was observed in
Gambian and Kenyan populations, with marked individ-
ual variations [27,28].
The higher prevalence of cellular proliferative responses to
the modified MSP119  noted in this study might be
explained by structural changes induced by the modifica-
tions. It has been suggested that the relatively poor cellu-
lar response to MSP119 is due to its structural complexity
and resistance to proteases. Thus with 6 disulfide bonds it
is impossible to load MSP119 onto MHC class II molecules
and it can only be available for loading when the bonds
have been reduced [29,30]. A form of MSP119 that is more
accessible to proteases would allow improved processing
by antigen-presenting cells (APC), which could enhance
the cellular responses and thus vaccine efficacy [29].
Human PBMC recognized and responded significantly to
eight out of ten variants, which had been designed to
either reduce or abolish the binding of known blocking
mAbs [21] (Figure 1). Among those individuals whose
cells responded, the prevalence of the responses to each
variant ranged from 7% to 64% of the population. More
people responded to the 27+31+34+43 variant than any
of the other variants tested (Figure 2). The ability of the
cells to respond to more than one variant was age depend-
ent, thus cells from adults responded to more variants
than the cells from children. This suggests a possible role
of previous and repeated exposure to infection in the
breadth of recognition and response to these variants (Fig-
ure 3).
The two mutant proteins with four amino acid substitu-
tions designated 27+31+34+43 and 15+27+31+43, char-
acterized as having epitopes for MSP1-processing
inhibitory antibodies, but no binding affinity for known
blocking mAbs [21] were the most frequently recognized
and they induced some of strongest cell responses
observed. The 27+31+34+43 mutant induced the strong-
est proliferative response (SI up to 360) and was the anti-
gen most frequently recognized by cells from malaria-
exposed adults and children. Each individual that
responded to the 15+27+31+43 variant also responded
either with equal or greater intensity to the 27+31+34+43
variant, suggesting a better recognition of the
27+31+34+43 variant by the responding cells. This is
attributable to the Tyr34→Ser modification in the
27+31+34+43 MSP119  variant compared with the
Asn15→Arg substitution in the 15+27+31+43 variant.
This result is consistent with the suggested role of Tyr34 at
the interface between the two epidermal-growth factor
(EGF) domains in providing structural stability; the
replacement of tyrosine by serine may result in an antigen
that can be processed more readily. From these results,
and the earlier antigenicity studies, the 27+31+34+43
MSP119 variant would be a favored variant for develop-
ment of a MSP1-based vaccine. However, additional stud-
ies are needed to determine whether the difference in the
cellular responses to these two closely related proteins is a
result of recognition by individual cell types (host factors)
or a result of the structural perturbations due to the amino
acid substitutions in the MSP1 sequence.
Conclusion
This study provides a possible basis to support the use of
the 27+31+34+43 and 15+27+31+43 MSP119 proteins as
engineered immunogens to induce improved cellular
responses and provide the T-cell help for the production
of protective MSP1 processing-inhibitory antibodies.
Unlike the wild-type MSP119 protein it is expected that
these proteins will not induce blocking antibody specifici-
ties. However, there is a need to carry out more detailed
studies of cellular responses to MSP119 variants with a
larger sample size. In order to understand the importance
of these modifications in antigen presentation, it wouldMalaria Journal 2009, 8:263 http://www.malariajournal.com/content/8/1/263
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be useful to properly characterize the phenotypes of the
proliferating cells. In addition the role of individual host
genetics, and other factors in the modulation of cellular
responses to these variants cannot be overemphasized.
The potential in vitro correlates of protective immunity
defined in this study represent an important step forward
in the search for and evaluation of an efficient MSP1-
based malaria vaccine.
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